GlassScriptPhysician profile
Michael M Miller
NPI 1376552315
$1,111.51
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $160 · 2021: $515 · 2022: $222.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $563.53 | 2019-2022 | |
| Aspira Women'S Health INC | $172.78 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.54 | 2019-2021 | |
| Myovant Sciences INC. | $88.55 | 2021-2022 | |
| Pfizer INC. | $47.93 | 2021-2022 | |
| Avion Pharmaceuticals | $39.39 | 2021 | |
| Merck Sharp & Dohme LLC | $37.42 | 2019-2021 | |
| Exeltis, USA INC. | $14.25 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.38 | 2021 | |
| Lupin INC. | $11.96 | 2020 | |
| Therapeuticsmd, INC. | $11.78 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.